| Drug |
Company |
$ Million |
Change From 2005 |
Notes |
| Truvada |
Gilead |
1,194 |
+210% |
|
| Kaletra |
Abbott |
1,135 |
+13% |
|
| Combivir |
GlaxoSmithKline |
977 |
-8% |
|
| Reyataz |
Bristol-Myers Squibb |
931 |
+34% |
|
| Sustiva |
Bristol-Myers Squibb |
791 |
+16% |
Includes $76 million related to Atripla sales |
| Viread |
Gilead |
689 |
-12% |
|
| Trizivir |
GlaxoSmithKline |
496 |
-10% |
|
| Epzicom |
GlaxoSmithKline |
446 |
+207% |
|
| Epivir |
GlaxoSmithKline |
374 |
-11% |
|
| Viramune |
Boehringer-Ingelheim |
353 |
-4% |
Estimate, based on 276 Euros |
| Crixivan |
Merck |
327 |
-6% |
|
| Fuzeon |
Roche |
250 |
+19% |
Estimate, based on 312 Swiss Francs |
| Lexiva/Agenerase |
GlaxoSmithKline |
242 |
+19% |
|
| Ziagen |
GlaxoSmithKline |
216 |
-13% |
|
| Atripla |
Gilead |
206 |
- |
Gilead recorded 100% of Atripla sales, then paid BMS $76 million for the efavirenz |
| Zerit |
Bristol-Myers Squibb |
155 |
-18% |
|
| Invirase/Fortovase |
Roche |
145 |
+28% |
Estimate, based on 182 Swiss Francs |
| Aptivus |
Boehringer-Ingelheim |
67 |
- |
Estimate, based on 53 Euros |
| Emtriva |
Gilead |
36 |
-13% |
|
| TOTAL |
|
9,030 |
+14% |
|
|
* Does not include unreported drugs (Videx, Norvir, Viracept, Rescriptor, Retrovir)
Source: AIDSMeds.com based on SEC filings.
|
This article was provided by Treatment Action Group. It is a part of the publication TAGline.
Email
Print-Friendly
Glossary
PDF
